[go: up one dir, main page]

WO2024095053A1 - Novel non-oral formulations of factor xa inhibitors and process for preparation thereof - Google Patents

Novel non-oral formulations of factor xa inhibitors and process for preparation thereof Download PDF

Info

Publication number
WO2024095053A1
WO2024095053A1 PCT/IB2022/062795 IB2022062795W WO2024095053A1 WO 2024095053 A1 WO2024095053 A1 WO 2024095053A1 IB 2022062795 W IB2022062795 W IB 2022062795W WO 2024095053 A1 WO2024095053 A1 WO 2024095053A1
Authority
WO
WIPO (PCT)
Prior art keywords
factor
formulation
inhibitor
inhibitors
surface active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2022/062795
Other languages
French (fr)
Inventor
Tathagata Dutta
Himanshu Agrawal
Manisha MULCHANDANI
Jyoti LOOMBA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jodas Expoim Pvt Ltd
Original Assignee
Jodas Expoim Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jodas Expoim Pvt Ltd filed Critical Jodas Expoim Pvt Ltd
Publication of WO2024095053A1 publication Critical patent/WO2024095053A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Definitions

  • the present invention relates to a novel non-oral formulation of factor Xa inhibitors comprising factor Xa inhibitor and pharmaceutically acceptable excipients selected from vehicles, surface active agents, co-solvents and stabilizers.
  • the present invention also relates to a process for preparing novel formulation of factor Xa inhibitor for non-oral route of administration.
  • the present invention also relates to a novel non-oral formulation of factor Xa inhibitors for parenteral, topical, nasal, transdermal and ophthalmic administration.
  • Factor Xa inhibitors are small molecules that selectively and reversibly bind to the active site of activated factor X (Xa), which blocks the interaction with its substrate in a rapid and competitive fashion, therefore inhibiting the final effects of thrombin generation.
  • factor Xa inhibitors such as Apixaban, Razaxaban, Betrixaban Rivaroxaban, and Edoxaban.
  • Apixaban is a known compound having the below structure and molecular weight 459.50 g/mol.
  • Razaxaban is a known compound having the below structure and molecular weight 528.5 g/mol.
  • Edoxaban is a known compound having the below structure and molecular weight 548.1 g/mol.
  • Rivaroxaban is a known compound having the below structure and molecular weight 435.9 g/mol.
  • Betrixaban is a known compound having the below structure and molecular weight 451.9 g/mol.
  • U.S. patent application 2015/0224053 Al teaches a oral liquid formulation comprising Apixaban and a vehicle, the vehicle comprising water and at least two solubilizers selected from the group consisting of a non-ionic surfactant, an ionic surfactant, a hydrophilic polymer, ethanol, a polyhydric alcohol, a polyethylene glycol, and a carbohydrate, wherein a solubility of Apixaban in the vehicle is at least 0.50 mg/mL.
  • PCT application WO 2007/022165 A2 teaches a pharmaceutical formulation comprising a factor Xa inhibitor and a substituted-0-cyclodextrin as solubilizing agent wherein the formulation is in the form of an injectable formulation.
  • Non-oral formulation of factor Xa inhibitor such as Apixaban or Razaxaban or Edoxaban or Rivaroxaban or Betrixaban eases the administration in subconscious, non-cooperative or pediatric or geriatric patients who have difficulty in swallowing a dosage form through oral route.
  • Factor Xa inhibitors such as Apixaban or Razaxaban are weak base.
  • Apixaban has pH dependent instability and its free base form has extremely low aqueous solubility which is less than 0.04 mg/mL.
  • Edoxaban and Rivaroxaban also have low aqueous solubility, 0.14 mg/mL and 0.025 mg/mL, respectively.
  • Anticipated human dose of Apixaban or Razaxaban or Edoxaban or Rivaroxaban or Betrixaban is about 2.5 to 15 mg.
  • a solution of high drug concentration for example 2 mg/mL. Since, the solubility of Apixaban or Razaxaban or Edoxaban or Rivaroxaban could not be increased to needed level i.e. 2 mg/mL, by adjusting pH in physiological range [pH 1.2-6.8] due to pH dependent instability.
  • a novel co-solvency approach is proposed for current formulation.
  • the objective of the present invention is to provide a novel non-oral formulation of factor Xa inhibitors comprising factor Xa inhibitor and pharmaceutically acceptable excipients selected from vehicles, surface active agents, co- solvents and stabilizers.
  • Another objective of the present invention is to provide a non-oral formulation of factor Xa inhibitors wherein factor Xa inhibitors are selected from Apixaban, Razaxaban, Edoxaban, Rivaroxaban and Betrixaban.
  • Another objective of the present invention is to provide a non-oral formulation of factor Xa inhibitors prepared using pharmaceutically acceptable excipients present within permitted IIG limit.
  • Another objective of the present invention is to provide a process for preparing novel formulation of factor Xa inhibitor for non-oral route of administration.
  • Another objective of the present invention is to provide a novel non-oral formulation of factor Xa inhibitors for parenteral, topical, nasal, transdermal and ophthalmic administration.
  • the present invention provides a novel non-oral formulation of factor Xa inhibitors comprising factor Xa inhibitor and pharmaceutically acceptable excipients selected from vehicles, surface active agents, co-solvents and stabilizers.
  • One embodiment of the present invention provides a non-oral formulation of factor Xa inhibitors with excipients within permitted IIG limit for I.V. administration, wherein factor Xa inhibitors are selected from the group of Apixaban, Razaxaban, Edoxaban, Rivaroxaban and Betrixaban.
  • factor Xa inhibitors are selected from Apixaban, Razaxaban, Edoxaban, Rivaroxaban and Betrixaban.
  • Another embodiment of the present invention provides a non-oral formulation of factor Xa inhibitors comprising: a) factor Xa inhibitor, b) vehicles, c) surface active agents, and d) co- solvents.
  • Another embodiment of the present invention provides a non-oral formulation of factor Xa inhibitors comprising: a) factor Xa inhibitor, b) vehicles, c) surface active agents, d) stabilizers and e) co- solvents.
  • Another embodiment of the present invention provides a non-oral formulation of factor Xa inhibitors comprising: a) 0.001% to 10% w/w of factor Xa inhibitor, b) 5% to 90% w/w of vehicles, c) 0.001% to 40% w/w of surface active agents and d) 10% to 90% w/w of co- solvents.
  • Another embodiment of the present invention provides a non-oral formulation of factor Xa inhibitors comprising: a) 0.001% to 10% w/w of factor Xa inhibitor, b) 5% to 90% w/w of vehicles, c) 0.001% to 40% w/w of surface active agents, d) 10% to 90% w/w of co-solvents, and e) 1% to 30% w/w of stabilizers.
  • factor Xa inhibitors comprising: a) factor Xa inhibitor selected from Apixaban, Razaxaban, Edoxaban, Rivaroxaban and Betrixaban, b) water as vehicle, c) surface active agents selected from polyoxyethylene sorbitan fatty acid esters (Polysorbates), block copolymers of polyethylene glycol and propylene glycol (poloxamers), and d) co- solvents selected from alcohol, propylene glycol, ethyl alcohol, polyethylene glycol, glycerin, benzyl alcohol, dimethylsulfoxide, dimethylacetamide and combinations thereof.
  • factor Xa inhibitor selected from Apixaban, Razaxaban, Edoxaban, Rivaroxaban and Betrixaban
  • water as vehicle c) surface active agents selected from polyoxyethylene sorbitan fatty acid esters (Polysorbates), block copolymers of polyethylene glycol and propylene glycol (poloxamers), and d
  • factor Xa inhibitors comprising: a) factor Xa inhibitor selected from Apixaban, Razaxaban, Edoxaban, Rivaroxaban and Betrixaban, b) water as vehicle, c) surface active agents selected from polyoxyethylene sorbitan fatty acid esters (Polysorbates), block copolymers of polyethylene glycol and propylene glycol (poloxamers), d) co- solvents selected from alcohol, propylene glycol, ethyl alcohol, polyethylene glycol, glycerin, benzyl alcohol, dimethylsulfoxide, dimethylacetamide and combinations thereof and e) stabilizers selected from glycerin, propylene glycol, sorbitol, and mannitol.
  • factor Xa inhibitor selected from Apixaban, Razaxaban, Edoxaban, Rivaroxaban and Betrixaban
  • water as vehicle c) surface active agents selected from polyoxyethylene sorbitan fatty acid esters
  • Another embodiment of the present invention provides a non-oral formulation of factor Xa inhibitors comprising: a) 0.001% to 10% w/w of factor Xa inhibitor selected from Apixaban, Razaxaban, Edoxaban, Rivaroxaban and Betrixaban, b) 5% to 90% w/w of water as vehicle, c) 0.001% to 40% w/w of surface active agents selected from polyoxyethylene sorbitan fatty acid esters (Polysorbates), block copolymers of polyethylene glycol and propylene glycol (poloxamers), and d) 10% to 90% w/w of co-solvents selected from alcohol, propylene glycol, ethyl alcohol, polyethylene glycol, glycerin, benzyl alcohol, dimethylsulfoxide, dimethylacetamide and combinations thereof.
  • factor Xa inhibitors comprising: a) 0.001% to 10% w/w of factor Xa inhibitor selected from Apixaban, Razaxaban
  • Another embodiment of the present invention provides a non-oral formulation of factor Xa inhibitors comprising: a) 0.001% to 10% w/w of factor Xa inhibitor selected from Apixaban, Razaxaban, Edoxaban, Rivaroxaban and Betrixaban, b) 5% to 90% w/w of water as vehicle, f) 0.001% to 40% w/w of surface active agents selected from polyoxyethylene sorbitan fatty acid esters (Polysorbates), block copolymers of polyethylene glycol and propylene glycol (poloxamers), g) 10% to 90% w/w of co-solvents selected from alcohol, propylene glycol, ethyl alcohol, polyethylene glycol, glycerin, benzyl alcohol, dimethylsulfoxide, dimethylacetamide and combinations thereof and c) 1% to 30% w/w of stabilizers selected from glycerin, sorbitol, and mannitol.
  • surface active agents selected
  • Another embodiment of the present invention provides a process for preparing a non-oral formulation of factor Xa inhibitors.
  • Another embodiment of the present invention provides a process for preparing a non-oral formulation of factor Xa inhibitor for parenteral, topical, nasal, transdermal and opthalmic administration.
  • Another embodiment of the present invention provides a process for preparing a non-oral formulation of factor Xa inhibitor comprising: a) adding factor Xa inhibitor and excipients under continuous mixing using stirring, b) making the final volume with water for injection, and c) heating the mixture if required.
  • Another embodiment of the present invention provides a process for preparing a non-oral formulation of factor Xa inhibitor comprising: a) dissolving the surface active agent in vehicle, b) adding one or more co-solvents and factor Xa inhibitor in the vehicle under continuous mixing using stirring, c) making the final volume with water for injection, and d) heating the mixture if required.
  • Another embodiment of the present invention provides a process for preparing a non-oral formulation of factor Xa inhibitor comprising: a) dissolving the surface active agent in vehicle, b) adding one or more co-solvents, stabilizers and factor Xa inhibitor in the vehicle under continuous mixing using stirring, c) making the final volume with water for injection, and d) heating the mixture if required.
  • the solubility of Apixaban, Razaxaban, Edoxaban, Rivaroxaban and Betrixaban in this vehicle is atleast 1.5 mg/mL.
  • the present invention has better acceptability as compared to earlier claimed inventions of the same group of drugs.
  • the formulation is suitable for bolus injection, intravenous infusion, topical, nasal, transdermal and ophthalmic administration.
  • in another embodiment of the present invention is a method for treating the risk of stroke and systemic embolism in nonvalular atrial fibrillation patients and deep vein thrombosis and pulmonary embolism after hip or knee replacement surgery, administered to patient in need, thereof a non-oral formulation of Apixaban, Razaxaban, Edoxaban, Rivaroxaban and Betrixaban are therapeutically active.
  • the subject invention describes new formulations of factor Xa inhibitor such as Apixaban, Razaxaban, Edoxaban, Rivaroxaban and Betrixaban for administration which includes non-oral formulation and method for making and using the same.
  • Drug solubility is minimum requirement for designing any dosage form and it is more critical when designing a formulation of poorly soluble drug like factor Xa inhibitor such as Apixaban, Razaxaban, Edoxaban, Rivaroxaban and Betrixaban. Because of low solubility associated with factor Xa inhibitor such as Apixaban, Razaxaban, Edoxaban, Rivaroxaban and Betrixaban, the bioavailability is limited and hence, solubility enhancement is necessary.
  • factor Xa inhibitor such as Apixaban, Razaxaban, Edoxaban, Rivaroxaban and Betrixaban.
  • the method of making and using novel non-oral formulation of poorly soluble factor Xa inhibitor such as Apixaban, Razaxaban, Edoxaban, Rivaroxaban and Betrixaban disclosed in this invention addresses the enhancement of patient acceptability for same class of drugs.
  • the factor Xa inhibitor is selected from Apixaban, Razaxaban, Edoxaban, Rivaroxaban and Betrixaban.
  • the factor Xa inhibitor used in formulations of present invention is in the range of about 0.001% to 10% w/w of total weight of the formulation.
  • the vehicle used in the formulations of the present invention is water.
  • the vehicle used in formulations of present invention is in the range of about 5% to 90% w/w of total weight of the formulation.
  • the surface active agents used in the present invention are selected from nonionic surface active agents such as polyoxyethylene sorbitan fatty acid esters (Polysorbates), block copolymers of polyethylene glycol and propylene glycol (poloxamers), polyoxyethylene castor oil derivative, polyoxyglyceride, vitamin E polyethylene glycol succinate, and macrogol 15 hydroxystearate and combinations thereof.
  • nonionic surface active agents such as polyoxyethylene sorbitan fatty acid esters (Polysorbates), block copolymers of polyethylene glycol and propylene glycol (poloxamers), polyoxyethylene castor oil derivative, polyoxyglyceride, vitamin E polyethylene glycol succinate, and macrogol 15 hydroxystearate and combinations thereof.
  • the surface active agents used in formulations of present invention is in the range of about 0.001% to 40% w/w of total weight of the formulation.
  • the co- solvents used in the present invention are selected from alcohol, propylene glycol, ethyl alcohol, polyethylene glycol, glycerin, benzyl alcohol, ester of a medium or long chain fatty acid such as a mono- di- or triglyceride, phospholipids, dimethylsulfoxide, dimethylacetamide and combinations thereof.
  • the co- solvents used in formulations of present invention is in the range of about 1% to 90% w/w of total weight of the formulation.
  • the stabilizers used in the present invention are selected from glycerin, sorbitol, and mannitol.
  • the stabilizers used in formulations of present invention are in the range of about 1% to 90% w/w of total weight of the formulation.
  • the said invention is stable as confirmed from stability studies conducted on prepared formulations.
  • the product thus formulated can be used for treatment of risk of stroke, systemic embolism in patients with nonvalvular atrial fibrillation, deep vein thrombosis and pulmonary embolism after hip or knee replacement surgery.
  • the dosage must be individualized by treating clinician.
  • the formulation of the present invention is manufactured by dissolving surface active agent in vehicle followed by adding one or more co-solvent’s or co-solvent and stabilizer and finally adding factor Xa inhibitor in the vehicle under continuous mixing using stirring. Final volume was made up by water for injection. Mixture was heated at 40-80°C for 10-30 minutes if required, to obtain clear solution upon cooling to room temperature.
  • the solution was free from particulate matter by visual inspection and was filtered by sterilizing grade filter followed by aseptic filling into vials or ampoules or prefilled syringes. If required, the final product was sterilized by autoclaving.
  • Target fill volume was 3.5 mL including 0.5 mL overfill for vial or needle or ampoule hold up.
  • Example 2 The formulations of example 2 were prepared as per manufacturing process described in Example 1.
  • Example 4 The formulations of example 4 were prepared as per manufacturing process described in Example 1.
  • Example 5 The formulations of example 5 were prepared as per manufacturing process described in Example 1.
  • EXAMPLE 6 The formulations of example 6 were prepared as per manufacturing process described in Example 1.
  • Example 7 The formulations of example 7 were prepared as per manufacturing process described in Example 1.
  • Example 8 The formulations of example 8 were prepared as per manufacturing process described in Example 1.
  • Example 9 The formulations of example 9 were prepared as per manufacturing process described in Example 1.
  • Table No. 11 Composition for formulation 11 The formulations of example 11 were prepared as per manufacturing process described in Example 1.
  • Example 12 The formulations of example 12 were prepared as per manufacturing process described in Example 1.
  • Example 13 The formulations of example 13 were prepared as per manufacturing process described in Example 1.
  • Example 14 The formulations of example 14 were prepared as per manufacturing process described in Example 1.
  • Table No. 16 Composition for formulation 16 The formulations of example 16 were prepared as per manufacturing process described in Example 1.
  • Example 17 The formulations of example 17 were prepared as per manufacturing process described in Example 1.
  • Example 18 The formulations of example 18 were prepared as per manufacturing process described in Example 1.
  • Example 19 The formulations of example 19 were prepared as per manufacturing process described in Example 1.
  • Example 20 The formulations of example 20 were prepared as per manufacturing process described in Example 1.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to a novel non-oral formulation of factor Xa inhibitors comprising factor Xa inhibitor and pharmaceutically acceptable excipients selected from vehicles, surface active agents, co-solvents and stabilizers. The present invention also relates to a process for preparing novel formulation of factor Xa inhibitor for non-oral route of administration. The present invention also relates to a novel non-oral formulation of factor Xa inhibitors for parenteral, topical, nasal, transdermal and ophthalmic administration.

Description

NOVEL NON-ORAL FORMULATIONS OF FACTOR Xa INHIBITORS AND PROCESS FOR PREPARATION THEREOF
FIELD OF INVENTION
The present invention relates to a novel non-oral formulation of factor Xa inhibitors comprising factor Xa inhibitor and pharmaceutically acceptable excipients selected from vehicles, surface active agents, co-solvents and stabilizers.
The present invention also relates to a process for preparing novel formulation of factor Xa inhibitor for non-oral route of administration.
The present invention also relates to a novel non-oral formulation of factor Xa inhibitors for parenteral, topical, nasal, transdermal and ophthalmic administration.
BACKGROUND OF INVENTION
Factor Xa inhibitors are small molecules that selectively and reversibly bind to the active site of activated factor X (Xa), which blocks the interaction with its substrate in a rapid and competitive fashion, therefore inhibiting the final effects of thrombin generation.
Several factor Xa inhibitors, such as Apixaban, Razaxaban, Betrixaban Rivaroxaban, and Edoxaban.
Apixaban is a known compound having the below structure and molecular weight 459.50 g/mol.
Figure imgf000002_0001
Razaxaban is a known compound having the below structure and molecular weight 528.5 g/mol.
Figure imgf000003_0001
Edoxaban is a known compound having the below structure and molecular weight 548.1 g/mol.
Figure imgf000003_0002
Rivaroxaban is a known compound having the below structure and molecular weight 435.9 g/mol.
Figure imgf000003_0003
Betrixaban is a known compound having the below structure and molecular weight 451.9 g/mol.
Figure imgf000004_0001
U.S. patent application 2015/0224053 Al teaches a oral liquid formulation comprising Apixaban and a vehicle, the vehicle comprising water and at least two solubilizers selected from the group consisting of a non-ionic surfactant, an ionic surfactant, a hydrophilic polymer, ethanol, a polyhydric alcohol, a polyethylene glycol, and a carbohydrate, wherein a solubility of Apixaban in the vehicle is at least 0.50 mg/mL.
PCT application WO 2007/022165 A2 teaches a pharmaceutical formulation comprising a factor Xa inhibitor and a substituted-0-cyclodextrin as solubilizing agent wherein the formulation is in the form of an injectable formulation.
Non-oral formulation of factor Xa inhibitor such as Apixaban or Razaxaban or Edoxaban or Rivaroxaban or Betrixaban eases the administration in subconscious, non-cooperative or pediatric or geriatric patients who have difficulty in swallowing a dosage form through oral route.
Factor Xa inhibitors such as Apixaban or Razaxaban are weak base. Reportedly, Apixaban has pH dependent instability and its free base form has extremely low aqueous solubility which is less than 0.04 mg/mL. Similarly, Edoxaban and Rivaroxaban also have low aqueous solubility, 0.14 mg/mL and 0.025 mg/mL, respectively.
Anticipated human dose of Apixaban or Razaxaban or Edoxaban or Rivaroxaban or Betrixaban is about 2.5 to 15 mg. To achieve a practical non-oral dose of less than 5 mL, a solution of high drug concentration, for example 2 mg/mL, is required. Since, the solubility of Apixaban or Razaxaban or Edoxaban or Rivaroxaban could not be increased to needed level i.e. 2 mg/mL, by adjusting pH in physiological range [pH 1.2-6.8] due to pH dependent instability. Hence, a novel co-solvency approach is proposed for current formulation.
OBJECTIVE OF INVENTION
The objective of the present invention is to provide a novel non-oral formulation of factor Xa inhibitors comprising factor Xa inhibitor and pharmaceutically acceptable excipients selected from vehicles, surface active agents, co- solvents and stabilizers.
Another objective of the present invention is to provide a non-oral formulation of factor Xa inhibitors wherein factor Xa inhibitors are selected from Apixaban, Razaxaban, Edoxaban, Rivaroxaban and Betrixaban.
Another objective of the present invention is to provide a non-oral formulation of factor Xa inhibitors prepared using pharmaceutically acceptable excipients present within permitted IIG limit.
Another objective of the present invention is to provide a process for preparing novel formulation of factor Xa inhibitor for non-oral route of administration.
Another objective of the present invention is to provide a novel non-oral formulation of factor Xa inhibitors for parenteral, topical, nasal, transdermal and ophthalmic administration.
SUMMARY OF INVENTION
Accordingly, the present invention provides a novel non-oral formulation of factor Xa inhibitors comprising factor Xa inhibitor and pharmaceutically acceptable excipients selected from vehicles, surface active agents, co-solvents and stabilizers.
One embodiment of the present invention provides a non-oral formulation of factor Xa inhibitors with excipients within permitted IIG limit for I.V. administration, wherein factor Xa inhibitors are selected from the group of Apixaban, Razaxaban, Edoxaban, Rivaroxaban and Betrixaban.
Another embodiment of the present invention provides a liquid formulation of factor Xa inhibitors, wherein factor Xa inhibitors are selected from Apixaban, Razaxaban, Edoxaban, Rivaroxaban and Betrixaban.
Another embodiment of the present invention provides a non-oral formulation of factor Xa inhibitors comprising: a) factor Xa inhibitor, b) vehicles, c) surface active agents, and d) co- solvents.
Another embodiment of the present invention provides a non-oral formulation of factor Xa inhibitors comprising: a) factor Xa inhibitor, b) vehicles, c) surface active agents, d) stabilizers and e) co- solvents.
Another embodiment of the present invention provides a non-oral formulation of factor Xa inhibitors comprising: a) 0.001% to 10% w/w of factor Xa inhibitor, b) 5% to 90% w/w of vehicles, c) 0.001% to 40% w/w of surface active agents and d) 10% to 90% w/w of co- solvents.
Another embodiment of the present invention provides a non-oral formulation of factor Xa inhibitors comprising: a) 0.001% to 10% w/w of factor Xa inhibitor, b) 5% to 90% w/w of vehicles, c) 0.001% to 40% w/w of surface active agents, d) 10% to 90% w/w of co-solvents, and e) 1% to 30% w/w of stabilizers.
Another embodiment of the present invention provides a non-oral formulation of factor Xa inhibitors comprising: a) factor Xa inhibitor selected from Apixaban, Razaxaban, Edoxaban, Rivaroxaban and Betrixaban, b) water as vehicle, c) surface active agents selected from polyoxyethylene sorbitan fatty acid esters (Polysorbates), block copolymers of polyethylene glycol and propylene glycol (poloxamers), and d) co- solvents selected from alcohol, propylene glycol, ethyl alcohol, polyethylene glycol, glycerin, benzyl alcohol, dimethylsulfoxide, dimethylacetamide and combinations thereof.
Another embodiment of the present invention provides a non-oral formulation of factor Xa inhibitors comprising: a) factor Xa inhibitor selected from Apixaban, Razaxaban, Edoxaban, Rivaroxaban and Betrixaban, b) water as vehicle, c) surface active agents selected from polyoxyethylene sorbitan fatty acid esters (Polysorbates), block copolymers of polyethylene glycol and propylene glycol (poloxamers), d) co- solvents selected from alcohol, propylene glycol, ethyl alcohol, polyethylene glycol, glycerin, benzyl alcohol, dimethylsulfoxide, dimethylacetamide and combinations thereof and e) stabilizers selected from glycerin, propylene glycol, sorbitol, and mannitol.
Another embodiment of the present invention provides a non-oral formulation of factor Xa inhibitors comprising: a) 0.001% to 10% w/w of factor Xa inhibitor selected from Apixaban, Razaxaban, Edoxaban, Rivaroxaban and Betrixaban, b) 5% to 90% w/w of water as vehicle, c) 0.001% to 40% w/w of surface active agents selected from polyoxyethylene sorbitan fatty acid esters (Polysorbates), block copolymers of polyethylene glycol and propylene glycol (poloxamers), and d) 10% to 90% w/w of co-solvents selected from alcohol, propylene glycol, ethyl alcohol, polyethylene glycol, glycerin, benzyl alcohol, dimethylsulfoxide, dimethylacetamide and combinations thereof.
Another embodiment of the present invention provides a non-oral formulation of factor Xa inhibitors comprising: a) 0.001% to 10% w/w of factor Xa inhibitor selected from Apixaban, Razaxaban, Edoxaban, Rivaroxaban and Betrixaban, b) 5% to 90% w/w of water as vehicle, f) 0.001% to 40% w/w of surface active agents selected from polyoxyethylene sorbitan fatty acid esters (Polysorbates), block copolymers of polyethylene glycol and propylene glycol (poloxamers), g) 10% to 90% w/w of co-solvents selected from alcohol, propylene glycol, ethyl alcohol, polyethylene glycol, glycerin, benzyl alcohol, dimethylsulfoxide, dimethylacetamide and combinations thereof and c) 1% to 30% w/w of stabilizers selected from glycerin, sorbitol, and mannitol.
Another embodiment of the present invention provides a process for preparing a non-oral formulation of factor Xa inhibitors.
Another embodiment of the present invention provides a process for preparing a non-oral formulation of factor Xa inhibitor for parenteral, topical, nasal, transdermal and opthalmic administration.
Another embodiment of the present invention provides a process for preparing a non-oral formulation of factor Xa inhibitor comprising: a) adding factor Xa inhibitor and excipients under continuous mixing using stirring, b) making the final volume with water for injection, and c) heating the mixture if required.
Another embodiment of the present invention provides a process for preparing a non-oral formulation of factor Xa inhibitor comprising: a) dissolving the surface active agent in vehicle, b) adding one or more co-solvents and factor Xa inhibitor in the vehicle under continuous mixing using stirring, c) making the final volume with water for injection, and d) heating the mixture if required.
Another embodiment of the present invention provides a process for preparing a non-oral formulation of factor Xa inhibitor comprising: a) dissolving the surface active agent in vehicle, b) adding one or more co-solvents, stabilizers and factor Xa inhibitor in the vehicle under continuous mixing using stirring, c) making the final volume with water for injection, and d) heating the mixture if required.
DETAILED DESCRIPTION OF THE INVENTION
The term "comprising", which is synonymous with "including", "containing", or "characterized by" here is defined as being inclusive or open-ended, and does not exclude additional, unrecited elements or method steps, unless the context clearly requires otherwise.
The solubility of Apixaban, Razaxaban, Edoxaban, Rivaroxaban and Betrixaban in this vehicle is atleast 1.5 mg/mL. The present invention has better acceptability as compared to earlier claimed inventions of the same group of drugs. In an embodiment of present invention, the formulation is suitable for bolus injection, intravenous infusion, topical, nasal, transdermal and ophthalmic administration.
In another embodiment of the present invention is a method for treating the risk of stroke and systemic embolism in nonvalular atrial fibrillation patients and deep vein thrombosis and pulmonary embolism after hip or knee replacement surgery, administered to patient in need, thereof a non-oral formulation of Apixaban, Razaxaban, Edoxaban, Rivaroxaban and Betrixaban are therapeutically active.
The subject invention describes new formulations of factor Xa inhibitor such as Apixaban, Razaxaban, Edoxaban, Rivaroxaban and Betrixaban for administration which includes non-oral formulation and method for making and using the same.
Drug solubility is minimum requirement for designing any dosage form and it is more critical when designing a formulation of poorly soluble drug like factor Xa inhibitor such as Apixaban, Razaxaban, Edoxaban, Rivaroxaban and Betrixaban. Because of low solubility associated with factor Xa inhibitor such as Apixaban, Razaxaban, Edoxaban, Rivaroxaban and Betrixaban, the bioavailability is limited and hence, solubility enhancement is necessary.
The method of making and using novel non-oral formulation of poorly soluble factor Xa inhibitor such as Apixaban, Razaxaban, Edoxaban, Rivaroxaban and Betrixaban disclosed in this invention addresses the enhancement of patient acceptability for same class of drugs.
In accordance with current invention, it was observed that water solubility of factor Xa inhibitor was sufficiently increased to allow preparation of aqueous based non-oral formulation by using factor Xa inhibitor with surface active agents and cosolvents and solvent and solubilising agents and stabilizers.
Many different category of water miscible co-solvent system and solubilizing agents have proved to be unacceptable for liquid formulation of factor Xa inhibitor due to the limited solubility of Apixaban, Razaxaban, Edoxaban, Rivaroxaban and Betrixaban sufficiently to provide a drug concentration of at least 1.5 mg/mL at acceptable administrable volume.
The factor Xa inhibitor is selected from Apixaban, Razaxaban, Edoxaban, Rivaroxaban and Betrixaban.
The factor Xa inhibitor used in formulations of present invention is in the range of about 0.001% to 10% w/w of total weight of the formulation.
The vehicle used in the formulations of the present invention is water.
The vehicle used in formulations of present invention is in the range of about 5% to 90% w/w of total weight of the formulation.
The surface active agents used in the present invention are selected from nonionic surface active agents such as polyoxyethylene sorbitan fatty acid esters (Polysorbates), block copolymers of polyethylene glycol and propylene glycol (poloxamers), polyoxyethylene castor oil derivative, polyoxyglyceride, vitamin E polyethylene glycol succinate, and macrogol 15 hydroxystearate and combinations thereof.
The surface active agents used in formulations of present invention is in the range of about 0.001% to 40% w/w of total weight of the formulation.
The co- solvents used in the present invention are selected from alcohol, propylene glycol, ethyl alcohol, polyethylene glycol, glycerin, benzyl alcohol, ester of a medium or long chain fatty acid such as a mono- di- or triglyceride, phospholipids, dimethylsulfoxide, dimethylacetamide and combinations thereof.
The co- solvents used in formulations of present invention is in the range of about 1% to 90% w/w of total weight of the formulation.
The stabilizers used in the present invention are selected from glycerin, sorbitol, and mannitol.
The stabilizers used in formulations of present invention are in the range of about 1% to 90% w/w of total weight of the formulation.
The said invention is stable as confirmed from stability studies conducted on prepared formulations.
The product thus formulated can be used for treatment of risk of stroke, systemic embolism in patients with nonvalvular atrial fibrillation, deep vein thrombosis and pulmonary embolism after hip or knee replacement surgery. As with any potent drug, the dosage must be individualized by treating clinician.
The formulation of the present invention is manufactured by dissolving surface active agent in vehicle followed by adding one or more co-solvent’s or co-solvent and stabilizer and finally adding factor Xa inhibitor in the vehicle under continuous mixing using stirring. Final volume was made up by water for injection. Mixture was heated at 40-80°C for 10-30 minutes if required, to obtain clear solution upon cooling to room temperature.
The solution was free from particulate matter by visual inspection and was filtered by sterilizing grade filter followed by aseptic filling into vials or ampoules or prefilled syringes. If required, the final product was sterilized by autoclaving. Target fill volume was 3.5 mL including 0.5 mL overfill for vial or needle or ampoule hold up.
The following examples describe the nature of the invention and are given only for the purpose of illustrating the present invention in more detail and are not limitative.
EXAMPLE 1
Table No. 1: Composition for formulation 1
Figure imgf000012_0001
Figure imgf000013_0001
Manufacturing process
Dissolving Polysorbate 80 in water followed by adding Propylene glycol, Alcohol and finally adding Apixaban in the vehicle. Each component was added under continuous mixing using stirring. Final volume was made up by water for injection. Mixture was heated at 55-60°C for 10-30 minutes if required, to obtain clear solution upon cooling to room temperature. The solution was free from particulate matter by visual inspection and was filtered by sterilizing grade filter followed by aseptic filling into vials or ampoules or prefilled syringes. If required, the final product was sterilized by autoclaving. Target fill volume was 3.5 mL including 0.5 mL overfill for vial or needle or ampoules hold up.
EXAMPLE 2
Figure imgf000013_0002
The formulations of example 2 were prepared as per manufacturing process described in Example 1.
EXAMPLE 3
Figure imgf000013_0003
Figure imgf000014_0001
The formulations of example 3 were prepared as per manufacturing process described in Example 1. EXAMPLE 4
Table No. 4: Composition for formulation 4
Figure imgf000014_0002
The formulations of example 4 were prepared as per manufacturing process described in Example 1.
EXAMPLE 5
Table No. 5: Composition for formulation 5
Figure imgf000014_0003
The formulations of example 5 were prepared as per manufacturing process described in Example 1. EXAMPLE 6
Figure imgf000015_0001
The formulations of example 6 were prepared as per manufacturing process described in Example 1.
EXAMPLE 7 Table No. 7: Composition for formulation 7
Figure imgf000015_0002
The formulations of example 7 were prepared as per manufacturing process described in Example 1.
EXAMPLE 8
Figure imgf000015_0003
Figure imgf000016_0001
The formulations of example 8 were prepared as per manufacturing process described in Example 1.
EXAMPLE 9
Table No. 9: Composition for formulation 9
Figure imgf000016_0002
The formulations of example 9 were prepared as per manufacturing process described in Example 1.
EXAMPLE 10
Table No. 10: Composition for formulation 10
Figure imgf000016_0003
The formulations of example 10 were prepared as per manufacturing process described in Example 1. EXAMPLE 11
Table No. 11: Composition for formulation 11
Figure imgf000017_0001
The formulations of example 11 were prepared as per manufacturing process described in Example 1.
EXAMPLE 12 Table No. 12: Composition for formulation 12
Figure imgf000017_0002
The formulations of example 12 were prepared as per manufacturing process described in Example 1.
EXAMPLE 13
Table No. 13: Composition for formulation 13
Figure imgf000017_0003
Figure imgf000018_0001
The formulations of example 13 were prepared as per manufacturing process described in Example 1.
EXAMPLE 14
Table No. 14: Composition for formulation 14
Figure imgf000018_0002
The formulations of example 14 were prepared as per manufacturing process described in Example 1.
EXAMPLE 15
Table No. 15: Composition for formulation 15
Figure imgf000018_0003
The formulations of example 15 were prepared as per manufacturing process described in Example 1. EXAMPLE 16
Table No. 16: Composition for formulation 16
Figure imgf000019_0001
The formulations of example 16 were prepared as per manufacturing process described in Example 1.
EXAMPLE 17 Table No. 17: Composition for formulation 17
Figure imgf000019_0002
The formulations of example 17 were prepared as per manufacturing process described in Example 1.
EXAMPLE 18
Table No. 18: Composition for formulation 18
Figure imgf000019_0003
Figure imgf000020_0001
The formulations of example 18 were prepared as per manufacturing process described in Example 1.
EXAMPLE 19
Table No. 19: Composition for formulation 19
Figure imgf000020_0002
The formulations of example 19 were prepared as per manufacturing process described in Example 1.
EXAMPLE 20
Table No. 20: Composition for formulation 20
Figure imgf000020_0003
The formulations of example 20 were prepared as per manufacturing process described in Example 1.
While the invention has been described with reference to a particular embodiment, it will be understood by those expert in the skill that various alterations may be made without deviating from the scope of invention. In addition to this, several alterations may be made to acclimatize a particular invention without deviating from the major scope. It is believed that the invention must not be restricted to particular embodiment disclosed as the best mode anticipated for carrying out of this invention, but then the invention will include all.

Claims

WE CLAIM:
1. A novel non-oral formulation of factor Xa inhibitors comprising factor Xa inhibitor and pharmaceutically acceptable excipients selected from vehicles, surface active agents, co-solvents and stabilizers.
2. The formulation as claimed in claim 1, wherein factor Xa inhibitor is selected from the group of Apixaban, Razaxaban, Edoxaban, Rivaroxaban and Betrixaban.
3. The formulation as claimed in claim 1, wherein the said factor Xa inhibitor has solubility from 1.5 to about 2 mg/mL.
4. The formulation as claimed in claim 1, wherein vehicle is water.
5. The formulation as claimed in claim 1, wherein non-ionic surface active agents selected from polyoxyethylene sorbitan fatty acid esters (Polysorbates), block copolymers of polyethylene glycol and propylene glycol (poloxamers), polyoxyethylene castor oil derivative, polyoxyglyceride, vitamin E polyethylene glycol succinate, and macrogol 15 hydroxystearate and combinations thereof.
6. The formulation as claimed in claim 1, wherein co- solvents selected from alcohol, propylene glycol, ethyl alcohol, polyethylene glycol, glycerin, benzyl alcohol, ester of a medium or long chain fatty acid such as a mono- di- or triglyceride, phospholipids, dimethylsulfoxide, dimethylacetamide and combinations thereof.
7. The formulation as claimed in claim 1, wherein stabilizers are selected from glycerin, sorbitol, and mannitol.
8. The formulation as claimed in claims 1-8, wherein non-oral formulation of factor Xa inhibitors comprising: a) 0.001% to 5% w/w of factor Xa inhibitor selected from Apixaban, Razaxaban, Edoxaban, Rivaroxaban and Betrixaban, b) 5% to 90% w/w of water as vehicle, c) 0.001% to 40% w/w of surface active agents selected from polyoxyethylene sorbitan fatty acid esters (Polysorbates), block copolymers of polyethylene glycol and propylene glycol (poloxamers), and d) 10% to 90% w/w of co-solvents selected from alcohol, propylene glycol, ethyl alcohol, polyethylene glycol, glycerin, benzyl alcohol, dimethylsulfoxide, dimethylacetamide and combinations thereof.
9. The formulation as claimed in claims 1-8, wherein non-oral formulation of factor Xa inhibitors comprising: a) 0.001% to 5% w/w of factor Xa inhibitor selected from Apixaban, Razaxaban, Edoxaban, Rivaroxaban and Betrixaban, b) 5% to 90% w/w of water as vehicle, c) 0.001% to 40% w/w of surface active agents selected from polyoxyethylene sorbitan fatty acid esters (Polysorbates), block copolymers of polyethylene glycol and propylene glycol (poloxamers), d) 10% to 90% w/w of co-solvents selected from alcohol, propylene glycol, ethyl alcohol, polyethylene glycol, glycerin, benzyl alcohol, dimethylsulfoxide, dimethylacetamide and combinations thereof and e) 1% to 30% w/w of stabilizers selected from glycerin, sorbitol, and mannitol.
10. The process for the preparation of formulation as claimed in claim 1, wherein said a process comprising: a) dissolving the surface active agent in vehicle, b) adding one or more co-solvents and factor Xa inhibitor in the vehicle under continuous mixing using stirring, c) making the final volume with water for injection, and d) heating the mixture.
11. The process for the preparation of formulation as claimed in claim 1, wherein said a process comprising: a) dissolving the surface active agent in vehicle, b) adding one or more co-solvents, stabilizers and factor Xa inhibitor in the vehicle under continuous mixing using stirring, c) making the final volume with water for injection, and d) heating the mixture.
PCT/IB2022/062795 2022-11-04 2022-12-27 Novel non-oral formulations of factor xa inhibitors and process for preparation thereof Ceased WO2024095053A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202241063008 2022-11-04
IN202241063008 2022-11-04

Publications (1)

Publication Number Publication Date
WO2024095053A1 true WO2024095053A1 (en) 2024-05-10

Family

ID=90929850

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2022/062795 Ceased WO2024095053A1 (en) 2022-11-04 2022-12-27 Novel non-oral formulations of factor xa inhibitors and process for preparation thereof

Country Status (1)

Country Link
WO (1) WO2024095053A1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210299059A1 (en) * 2018-08-14 2021-09-30 Jiangsu Hengrui Medicine Co., Ltd. Injectable pharmaceutical composition and preparation method therefor
WO2022056326A1 (en) * 2020-09-11 2022-03-17 Elixir Medical Corporation Anticoagulant compounds, methods and devices for ophthalmic use
BR102021018969A2 (en) * 2020-09-25 2022-06-07 Universidade Federal Do Rio De Janeiro Rivaroxaban microemulsion-gel and rivaroxaban microemulsion-gel manufacturing process

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210299059A1 (en) * 2018-08-14 2021-09-30 Jiangsu Hengrui Medicine Co., Ltd. Injectable pharmaceutical composition and preparation method therefor
WO2022056326A1 (en) * 2020-09-11 2022-03-17 Elixir Medical Corporation Anticoagulant compounds, methods and devices for ophthalmic use
BR102021018969A2 (en) * 2020-09-25 2022-06-07 Universidade Federal Do Rio De Janeiro Rivaroxaban microemulsion-gel and rivaroxaban microemulsion-gel manufacturing process

Similar Documents

Publication Publication Date Title
RU2429837C2 (en) Pharmaceutical composition of taxan, solid composition of taxan, method of producing solid composition of taxan, composition for solubilisation of said solid composition of taxan and set of elements (kit) for composition of taxan for injections
CN101926757B (en) Liquid composition of indissolvable medicines and preparation method thereof
RU2345772C2 (en) Lyophilised compositions cci-779
JP2007519732A (en) Aqueous pharmaceutical composition of 2,6-diisopropylphenol (propofol) and use thereof
EA035079B1 (en) Diclofenac composition
JP6818019B2 (en) Injectable pharmaceutical composition of lefamulin
TW202245791A (en) Pharmaceutical formulation
JP5847942B2 (en) Taxane-based active ingredient-containing liquid composition, method for producing the same, and liquid formulation
JP2007515425A (en) Pharmaceutical composition
KR20150112975A (en) Stable pharmaceutical composition of clopidogrel free base for oral and parenteral delivery
EA016619B1 (en) Novel taxoid-based compositions
JPH06219948A (en) Antithrombin agent and its production
CN102958519B (en) Pharmaceutical composition containing paracetamol and its preparation method
AU2025242078A1 (en) Drug delivery formulations
WO2024095053A1 (en) Novel non-oral formulations of factor xa inhibitors and process for preparation thereof
JP2011529930A (en) Injectable taxane pharmaceutical composition
KR20210102936A (en) Stable anesthetic formulations and related dosage forms
RU2370261C2 (en) Stable emulsion for parenteral introduction of badly soluble in water compounds, which have anti-tumor activity, and method of its obtaining
CN119894500A (en) Pharmaceutical composition
LT5069B (en) Stable pharmaceutical form of an anticancer drug
US20250228815A1 (en) Lyophilized resiniferatoxin
CN108430454A (en) Fulvestrant composition
CN100467024C (en) Lornoxicam injection composition and preparation method thereof
CN113797167B (en) Reservoir preparation of celebrarphine
CN102198095A (en) Epoprostenol fat emulsion and preparation method thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22964322

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22964322

Country of ref document: EP

Kind code of ref document: A1